Literature DB >> 8976730

Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease.

K Norose1, A Yano.   

Abstract

AIMS/
BACKGROUND: To determine the functional properties and cytokine production profiles of melanoma specific cytotoxic T lymphocytes (CTLs) induced from peripheral blood leucocytes of two patients with Vogt-Koyanagi-Harada disease (VKH).
METHODS: Melanoma specific CTL lines were established by long term coculture with a human melanoma cell line (P-36). Cytotoxic activity against P-36 was measured by 51Cr release. The involvement of human leucocyte antigen (HLA) class I or class II molecules in the cytotoxicity of the CTL lines against P-36 was analysed using anti-HLA class I or anti-HLA class II monoclonal antibody (MAb). Surface molecules of CTL lines were analysed by flow cytometry using MAbs specific for CD4, CD8, CD16, CD25, CD56, HLA-DR, T cell antigen receptor (TCR) alpha beta and TCR gamma delta. Cytokine production and soluble interleukin 2 receptor (sIL-2R) secretion were determined by enzyme linked immunosorbent assays. mRNAs of cytokines were analysed using reverse transcription polymerase chain reaction (RT-PCR).
RESULTS: CTLs showed strong cytotoxic activity against P-36. The CTL activity of the cell lines against P-36 was inhibited by the anti-HLA-DR MAb, whereas the MAb specific for monomorphic determinants of HLA-A, B, and C failed to block lytic activity. Flow cytometry identified the following surface molecules: CD4+, CD8-, CD16-, CD25+, CD56-, HLA-DR+, TCR alpha beta +, and TCR gamma delta-. CTLs constitutively produced a high level of IL-6. IL-6 production and sIL-2R secretion of CTLs were enhanced when CTLs were stimulated with P-36. CTLs also produced high levels of interferon gamma (IFN-gamma) and IL-2, but not IL-4. mRNAs of IL-2 and IFN-gamma were detected by RT-PCR in the CTLs.
CONCLUSIONS: Melanoma specific HLADR restricted T helper 1 (Th1) CTLs may play a role in the immunopathogenesis of VKH.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8976730      PMCID: PMC505680          DOI: 10.1136/bjo.80.11.1002

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  35 in total

1.  Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.

Authors:  P Hersey; M MacDonald; S Schibeci; C Burns
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  A cell line and clones of lymphocytes from a healthy donor, with specificity to S-antigen.

Authors:  S Hirose; C G McAllister; K K Mittal; B P Vistica; T Shinohara; I Gery
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-11       Impact factor: 4.799

3.  Adoptive transfer of experimental autoimmune uveoretinitis in rats. Immunopathogenic mechanisms and histologic features.

Authors:  M Mochizuki; T Kuwabara; C McAllister; R B Nussenblatt; I Gery
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-01       Impact factor: 4.799

4.  Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

Authors:  L M Muul; P J Spiess; E P Director; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

Review 5.  Interleukin-2: inception, impact, and implications.

Authors:  K A Smith
Journal:  Science       Date:  1988-05-27       Impact factor: 47.728

6.  The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species.

Authors:  P Arcari; R Martinelli; F Salvatore
Journal:  Nucleic Acids Res       Date:  1984-12-11       Impact factor: 16.971

7.  Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens.

Authors:  M Yasukawa; J M Zarling
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

8.  Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer.

Authors:  J M Skibber; M T Lotze; I Uppenkamp; W Ross; S A Rosenberg
Journal:  J Surg Res       Date:  1987-06       Impact factor: 2.192

9.  Lysis of CD3 hybridoma targets by cloned human CD4 lymphocytes.

Authors:  A Hayward; A Boylston; P Beverley
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

10.  Two distinct cytotoxic T lymphocyte subpopulations in patients with Vogt-Koyanagi-Harada disease that recognize human melanoma cells.

Authors:  N Maezawa; A Yano
Journal:  Microbiol Immunol       Date:  1984       Impact factor: 1.955

View more
  23 in total

Review 1.  Current approach in the diagnosis and management of panuveitis.

Authors:  Reema Bansal; Vishali Gupta; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

2.  The positive role of lumbar puncture in the diagnosis of Vogt-Koyanagi-Harada disease: lymphocyte subsets in the aqueous humor and cerebrospinal fluid.

Authors:  Nobuyoshi Kitaichi; Hiroko Matoba; Shigeaki Ohno
Journal:  Int Ophthalmol       Date:  2007-01-09       Impact factor: 2.031

Review 3.  A review of immunologic diseases of the dog.

Authors:  N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1999-08-02       Impact factor: 2.046

4.  The association of systemic disorders with Vogt-Koyanagi-Harada and sympathetic ophthalmia.

Authors:  Ali Al-Halafi; Hassan Al Dhibi; Issam H Hamade; Charbel T Bou Chacra; Khalid F Tabbara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-06-30       Impact factor: 3.117

5.  Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition.

Authors:  Michel M Sun; Ralph D Levinson; Artur Filipowicz; Stephen Anesi; Henry J Kaplan; Wei Wang; Debra A Goldstein; Sapna Gangaputra; Robert T Swan; H Nida Sen; Lynn K Gordon
Journal:  Ocul Immunol Inflamm       Date:  2019-03-01       Impact factor: 3.070

6.  Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.

Authors:  Carl W Noble; Sapna S Gangaputra; Ian A Thompson; Amy Yuan; Andrea B Apolo; Jung-Min Lee; George N Papaliodis; Shilpa Kodati; Rachel Bishop; M Teresa Magone; Lucia Sobrin; H Nida Sen
Journal:  Ocul Immunol Inflamm       Date:  2019-04-23       Impact factor: 3.070

7.  Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease.

Authors:  M Kitamura; N Kitaichi; M Takeuchi; H Kitamei; K Namba; S-I Yamagishi; K Iwabuchi; K Onoé; S Ohno
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

8.  HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia.

Authors:  Alia Iqniebi; Ameera Gaafar; Atia Sheereen; Abdullah Al-Suliman; Gamal Mohamed; Khaled Al-Hussein; Khalid F Tabbara
Journal:  Mol Vis       Date:  2009-09-12       Impact factor: 2.367

9.  Trabecular meshwork depigmentation in Vogt-Koyanagi-Harada disease.

Authors:  Kazuomi Mizuuchi; Nobuyoshi Kitaichi; Kenichi Namba; Yukihiro Horie; Susumu Ishida; Shigeaki Ohno
Journal:  Jpn J Ophthalmol       Date:  2013-01-29       Impact factor: 2.447

10.  PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome.

Authors:  Qianli Meng; Xiaoli Liu; Peizeng Yang; Shengping Hou; Liping Du; Hongyan Zhou; Aize Kijlstra
Journal:  Mol Vis       Date:  2009-02-20       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.